ES2903136T3 - Clorhidrato de creatina para el tratamiento de la enfermedad de Huntington - Google Patents

Clorhidrato de creatina para el tratamiento de la enfermedad de Huntington Download PDF

Info

Publication number
ES2903136T3
ES2903136T3 ES16783719T ES16783719T ES2903136T3 ES 2903136 T3 ES2903136 T3 ES 2903136T3 ES 16783719 T ES16783719 T ES 16783719T ES 16783719 T ES16783719 T ES 16783719T ES 2903136 T3 ES2903136 T3 ES 2903136T3
Authority
ES
Spain
Prior art keywords
creatine
disease
composition
grams
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16783719T
Other languages
English (en)
Spanish (es)
Inventor
Mark Faulkner
Donald Miller
Grant Hatch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vireo Systems Inc
Original Assignee
Vireo Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vireo Systems Inc filed Critical Vireo Systems Inc
Application granted granted Critical
Publication of ES2903136T3 publication Critical patent/ES2903136T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
ES16783719T 2015-04-20 2016-04-20 Clorhidrato de creatina para el tratamiento de la enfermedad de Huntington Active ES2903136T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562150113P 2015-04-20 2015-04-20
PCT/US2016/028357 WO2016172148A1 (en) 2015-04-20 2016-04-20 Compositions and methods for neuroprotection and treatment of neurodegeneration

Publications (1)

Publication Number Publication Date
ES2903136T3 true ES2903136T3 (es) 2022-03-31

Family

ID=57128180

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16783719T Active ES2903136T3 (es) 2015-04-20 2016-04-20 Clorhidrato de creatina para el tratamiento de la enfermedad de Huntington

Country Status (7)

Country Link
US (3) US10245245B2 (https=)
EP (1) EP3285755B1 (https=)
JP (2) JP6882191B2 (https=)
CA (1) CA2983151C (https=)
ES (1) ES2903136T3 (https=)
PL (1) PL3285755T3 (https=)
WO (1) WO2016172148A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6882191B2 (ja) * 2015-04-20 2021-06-02 ビレオ システムズ インコーポレイテッド 神経保護および神経変性の治療のための組成物および方法
CA3095440A1 (en) * 2018-03-27 2019-10-03 Thermolife International, Llc Creatine and/or creatinine compositions and related methods
US11154499B2 (en) 2018-03-27 2021-10-26 Thermolife International, Llc Creatine and/or creatinine compositions and related methods
US11260096B2 (en) 2019-06-28 2022-03-01 Thermolife International, Llc Compositions for creatine supplementation in creatine non-responders
EP4247358A4 (en) * 2020-11-23 2024-10-16 VIREO Systems, Inc. Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE332127T1 (de) 1994-11-08 2006-07-15 Avicena Group Inc Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose
WO2002069740A1 (en) * 2001-03-02 2002-09-12 The Howard Foundation Compositions containing creatine and creatinine
US7608641B2 (en) 2003-05-15 2009-10-27 Board Of Regents Of The University Of Nebraska Creatine oral supplementation using creatine hydrochloride salt
US8354450B2 (en) * 2003-05-15 2013-01-15 Vireo Systems, Inc. Creatine oral supplementation using creatine hydrochloride salt
JP2008544254A (ja) 2005-06-13 2008-12-04 ストラタジーン カリフォルニア 別個の光学経路を有している蛍光の励起および検出のためのシステムおよび方法
AU2007249847A1 (en) 2006-05-11 2007-11-22 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
US7683043B2 (en) * 2006-06-06 2010-03-23 Xenoport, Inc. Creatine phosphate analog prodrugs, compositions and uses thereof
EP2162126A4 (en) * 2007-06-05 2013-08-28 Cryxa Llc MAGENTATE-RESISTANT COATED SOLUBLE CREATINE AND POLYETHYLENE GLYCOL COMPOSITION TO IMPROVE THE BONE RECEPTACY OF ORAL CREATINE
US8445466B2 (en) * 2010-04-08 2013-05-21 John H. Owoc Stable aqueous compositions comprising amide-protected bioactive creatine species and uses thereof
WO2015095199A1 (en) * 2013-12-16 2015-06-25 Vireo Systems, Inc. Method and composition for treating osteoarthritis
JP6882191B2 (ja) * 2015-04-20 2021-06-02 ビレオ システムズ インコーポレイテッド 神経保護および神経変性の治療のための組成物および方法

Also Published As

Publication number Publication date
US10583105B2 (en) 2020-03-10
JP2018513204A (ja) 2018-05-24
EP3285755A1 (en) 2018-02-28
JP6882191B2 (ja) 2021-06-02
PL3285755T3 (pl) 2022-02-21
US20160303061A1 (en) 2016-10-20
US11160776B2 (en) 2021-11-02
US10245245B2 (en) 2019-04-02
EP3285755A4 (en) 2018-12-05
CA2983151A1 (en) 2016-10-27
WO2016172148A1 (en) 2016-10-27
US20200316000A1 (en) 2020-10-08
JP2021120388A (ja) 2021-08-19
US20190224151A1 (en) 2019-07-25
EP3285755B1 (en) 2021-10-13
CA2983151C (en) 2024-03-05

Similar Documents

Publication Publication Date Title
US11160776B2 (en) Compositions and methods for neuroprotection and treatment of neurodegeneration
ES2393065T3 (es) Composiciones y procedimientos para el tratamiento de enfermedades mitocondriales
ES2640777T3 (es) Terapia anaplerótica para la enfermedad de Alzheimer
ES2731052T3 (es) Tratamiento de la enfermedad de Huntington usando laquinimod
ES2690061T3 (es) Composiciones para tratar la enfermedad de Parkinson
ES2728948T3 (es) Tratamiento de la inflamación cerebral usando Fenilacetato de L-Ornitina
ES2897453T3 (es) Aplicación de R-ketamina y sal de la misma como productos farmacéuticos
ES2666657T3 (es) Fenfluramina para uso en el tratamiento de síndrome de Dravet
ES2590259T3 (es) Compuestos y procedimientos para el tratamiento de convulsiones y trastornos paroxísticos
ES2279523T3 (es) Nuevo uso terapeutico de la l-carnitina o sus derivados acilados.
ES2729713T3 (es) Compuestos tricíclicos, composiciones que los comprenden y usos de los mismos
US11458141B2 (en) Aryl hydrocarbon receptor (AhR) agonists for the prevention and treatment of inflammatory disorders
BR112020022985A2 (pt) composições e métodos que usam um precursor de nicotinamida adenina dinucleotídeo (nad+) e pelo menos uma cetona ou um precursor de cetona
US20060127506A1 (en) Compositions of S-adenosyl-L-methionine
ES3031785T3 (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria
ES2613977T3 (es) Composiciones farmacéuticas con dosis elevadas de biotina
US20250304544A1 (en) Molephantin derivatives useful in the treatment of cancer
US20180207113A1 (en) Vivo intracellular reprogramming composition and method of making and using same
ES2972199T3 (es) Dosis y régimen terapéutico para la melatonina
WO2021063408A1 (zh) 制备治疗阿尔兹海默病的药物
CN114072154A (zh) 用于治疗精神障碍的加波沙朵和锂的组合物
ES2386831B1 (es) Uso de inhibidores de la actividad de las NO sintasas (NOS) y sus composiciones, en la elaboración de un medicamento para el tratamiento y la prevención de la prediabetes y la diabetes mellitus tipo 1 (DM1)
ES2814048B2 (es) Uso combinado de biotina y tiamina en el tratamiento de la enfermedad de huntington
ES2326355B1 (es) Acido 1-(di-n-propilacetilaminometil)-ciclohexilacetico.
KR20050031499A (ko) 뇌허혈성 질환의 예방 및 치료용 조성물